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Table.
All II aneurysm (35%) IIA stenosis (20%) CIA < 16 mm (46%)
Technical success, % (n ¼ 138) 93 Yes 93 No 93 ns Yes 82 No 96 P ¼ .015 Yes 95 No 92 ns
Endoleak, % 3 7 1 ns 0 4 ns 0 5 ns
Patency, %, 30d 1yr 5yr 95 86 82 98 87 78 93 86 83 ns 89 81 81 96 88 82 ns 92 84 84 97 89 80 ns
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sion of patients with internal iliac artery (IIA) stenosis,
narrow common iliac artery (CIA) diameters and IIA aneu-
rysm has precluded hypogastric preservation in most cases.
Methods: Data was prospectively collected on patients
with infrarenal or thoracoabdominal aortoiliac aneurysms
treated with helical-IBDs (H-IBD). Preoperative aneu-
rysmal characteristics, technical success, patency, reinter-
ventions and endoleaks were noted in accordance with
endovascular reporting standards. Survival and patency
were evaluated with life-table analyses and differences
among anatomic groups compared with log-rank tests.
T-tests and Fisher’s exact tests were used to compare
simple variables.
Results: Between 2003 and 2012, 138 Helical-IBD
devices were placed into 130 patients, beginning in 2008
with a novel device intended for short CIA aneurysms.
Median follow up was 16.2 months (range, 1-72 months)
with 30 day, 1 and 5 year survival rates of 99%, 90%, and
62% respectively. Overall technical success, endoleak and
branch patency, and outcomes between anatomically select
groups are summarised in the Table. No stent fractures or
component separations were noted in the IBDs or mating
devices. Based upon instructions for use for other devices,
only 20% of the patients in this study were candidates for
treatment with an IBD.
Conclusions: The H-IBD has high technical success,
which is detrimentally affected by tight IIA stenosis.
Patency was unaffected by challenging anatomy. The
minority of patients in this trial had anatomy amenable
for treatment with other devices.
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Objectives: To analyze long-term durability of endo-
vascular treatment (EVAR) for aorto-iliac aneurysm with
the use of iliac branch device (IBD).Methods: A prospective analysis of all patients under-
went EVAR with IBD between September 2007 and
December 2012 was carried out. Main clinical, anatomical
and technical data concerning pre, intra and postoperative
period were prospectively collected into a dedicated data-
base. Follow-up consisted of clinical examination, duplex
scan and computed tomography at 1, 6, 12 months and
yearly thereafter. Data were reported according to the
Kaplan-Meier method.
Results: Ninety-ﬁve EVAR procedures with IBD were
electively carried out in 91 patients. Among the 35 (36.8%)
bilateral iliac aneurysms, four patients (4.2%) received bilat-
eral IBD. Technical success was obtained in 98.9% of cases.
Median follow-up duration was 23.4 months (range 1-63
months). There was one IBD occlusion (1%). Estimated
60 months survival, freedom from reintervention and
branch occlusion was 79.7%, 88.3% and 98.1%, respec-
tively. Seven patients (7.3%), six of them treated for bilat-
eral iliac aneurysms, developed persistent buttock
claudication on the side of hypogastric exclusion whereas
no pelvic ischemic symptoms were observed on the side
of patent IBD.
Conclusions: EVAR for aortoiliac aneurysm using
IBD is durable procedure with low complications and rein-
terventions rates at ﬁve years follow-up. Since no buttock
claudication was observed in patients with patent IBD, it
could be proposed as ﬁrst line treatment whenever anatom-
ically feasible.
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Objectives: Standard surveillance after endovascular
aneurysm repair (EVAR) consists of contrast-enhanced
CT scans, usually at 1 month, 6 months and annually for
5 years. These are expensive and expose patients to neph-
rotoxic contrast and ionizing radiation. We hypothesized
that a normal CTA with no endoleak within 1 month after
EVAR predicts a low rate of future complications, which
would justify a reduction in subsequent CT scans.
Methods: We examined the medical records of 104
patients who underwent EVAR at a single hospital, review-
ing all postoperative CTA’s and noting any complications
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or endovascular intervention. Thirteen patients who had no
postoperative contrast-enhanced CT scans were excluded.
Our practice has been to obtain CTA’s at postoperative
months 1, 6, and 12 and then yearly for 5 years.
Results: The mean patient follow up was 3.4 6 2
years. Of 91 patients, 71 (78%) had a normal CTA at 1
month after EVAR without endoleak or other abnormality.
Four of these 71 (5.6%) developed late complications con-
sisting of three type II endoleaks and one type I endoleak,
which presented on postoperative days 240, 1135, 1383,
and 1294, respectively. Only one of the type II endoleaks
was accompanied by aneurysm sac growth requiring repair
and the small type I endoleak was also repaired.
Conclusions: For patients who have a normal CTA
with no endoleak one month after EVAR it is reasonable
to consider less frequent CTA surveillance as no signiﬁcant
complications requiring intervention occurred before three
years.
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Lumen and False Lumen Regression
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1EmoryUniversity, Atlanta,Ga; 2AtlantaVAMC,Atlanta,GaFig.Objectives: Despite optimal medical therapy of
uncomplicated Type B aortic dissections (TBAD), true
lumen narrowing and aneurysmal degeneration of the false
lumen can occur over the long-term (>6 months). The
efﬁcacy of thoracic stent-grafts (TEVAR) for aortic remod-
eling when placed at late time points remains controversial.
We studied post-TEVAR aortic volumetric changes in
these patients.
Methods: Utilizing tomographic scans, volumes of
multiple aortic compartments were calculated including
the stented true lumen (STL), peri-stented false lumen
(SFL), true lumen from distal stent to celiac axis (infra stent
true lumen, ISTL), and the corresponding false lumen
(ISFL). Cross-sectional areas were calculated at one centi-
meter intervals, collated, and volumetric ratios were
derived from preoperative values.
Results: From 2004-2011, twenty-one patients met
inclusion criteria. The time from index dissection to
TEVAR was 197 days or greater. The left subclavian artery
was covered in 71.4% of cases. Best-ﬁt line statistical regres-
sion analysis of volumetric change demonstrated increases
in ISTL and total TL volumes by 55% and 38%, respec-
tively (P < .05) at one year (Fig, A and B). SFL and
ISFL volumes decreased by 41% and 32%, respectively (P <
.05) (Fig, C and D).
Conclusions: TEVAR for aneurysmal degeneration
after long-term medical therapy of TBAD results in volu-
metric gain of the true lumen and false lumen regression.
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Objectives: Patients undergoing EVAR of AAA can
exhibit variations in sac behavior from complete regression
to expansion. We evaluated the impact of sac behavior at
one year follow up on late survival.
Methods: We used the Vascular Study Group of New
England (VSGNE) registry (2003-2011), to identify
EVAR patients with one year CT follow up. Aneurysm
sac enlargement >5 mm (SacEn) or decrease >5 mm
(SacDe) was deﬁned according to SVS guidelines and
predictors of change in sac size and impact of sac behavior
were assessed by multivariable methods.
Results: 1642 EVAR patients with one year follow up
were included. At 1 yr, 8% had SacIn, 72% had SacDe, and
20% had stable sac size. Independent predictors of SacIn
were urgent repair (OR, 2.9; 95% CI, 1.7-5.0; P < .01),
intraoperative type I/III endoleak (OR, 2.7; 95% CI,
1.1-6.9; P ¼ .03), hypogastric coverage (OR, 2.2; 95%
